A Lesson to Learn o...
Health Care: Drugs
Aastrom Biosciences Inc. (ASTM: NASDAQ)
$0.51 0.00 | -0.29%
06/18/13 - 03:59 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ASTM | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -61.19 | -77.60 | -66.55 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 16.70 | -0.88 | -0.51 |
| Net Income | 0.00 | 0.00 | |
| EPS | -0.08 | 0.00 |
Earnings for ASTM:
| EBITDA | -33.00 |
| REVENUE | 21.00K |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.12 | $-0.11 | $-0.46 | $-0.44 |
| Number of Analysts | 6 | 6 | 6 | 5 |
| High Estimate | $-0.08 | $-0.05 | $-0.29 | $-0.18 |
| Low Estimate | $-0.16 | $-0.15 | $-0.61 | $-0.95 |
| Prior Year | $-0.27 | $-0.22 | $-0.91 | $-0.46 |
| Growth Rate (Year over Year) | 55.56% | 52.27% | 49.08% | 5.04% |
Portfolios with ASTM
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserMark
- UserMy Portfolio As of 7/15/2012
- Userdonnieny7 Portfolio 1 Specu...
- ContributorBreakout Stocks Of The Week...
- Contributor10 Cheap Biotech Stocks Tha...
- Usermrtimrx WatchList
- UserMy Folly
- Userbosw119
- Usergellis1360 Portfolio 1
Latest ASTM Headlines from TheStreet
- Aastrom Biosciences Reports First Quarter 2013 Financial Results 05.08.13 | 04:05 pm
- Aastrom To Host First Quarter 2013 Investor Call On May 8, 2013 05.03.13 | 04:05 pm
- Aastrom To Hold Annual Meeting Of Shareholders On May 2, 2013 04.25.13 | 04:04 pm
- Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 04.19.13 | 09:04 am
- Aastrom Biosciences To Present At Multiple Conferences In April 04.09.13 | 04:04 pm
- Aastrom Biosciences Announces First Patients Enrolled In IxCELL-DCM Phase 2b Clinical Trial Of Ixmyelocel-T 04.04.13 | 09:04 am
- Aastrom Biosciences Announces Strategic Change In Research And Development Programs To Focus On Dilated Cardiomyopathy And Other Rare Disease Indications 03.27.13 | 08:03 am
- Aastrom Biosciences Reports Fourth-Quarter And Year-End 2012 Financial Results 03.18.13 | 04:03 pm
- Aastrom To Host Fourth Quarter 2012 Investor Call On March 18, 2013 03.12.13 | 04:03 pm
- Aastrom Board Of Directors Names Dominick C. Colangelo President And Chief Executive Officer 03.06.13 | 04:03 pm
Press Releases for ASTM
Partner Headlines for ASTM
- Is Takeda Interested In Aastrom Bio? - Seeking Alpha 02.27.13 | 09:02 am
- Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico - NASDAQ 09.13.12 | 05:09 pm
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- Talisman Energy UPGRADED to Buy and 2 Analyst-Upgraded Shares to Notice - Wall St. Cheat Sheet 07.24.12 | 06:07 am
- Analysts Release These New Equity Ratings Monday - Wall St. Cheat Sheet 06.04.12 | 03:06 am
- Follow the Analyst Leader: New Stock Coverage to Watch - Wall St. Cheat Sheet 05.31.12 | 04:05 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T - Benzinga 02.29.12 | 04:02 pm
- 10 Biotech Stocks Undervalued By Levered Free Cash Flows - Seeking Alpha 12.07.11 | 08:12 am
- Aastrom Bio: Final RESTORE Data Looks Solid - Seeking Alpha 11.15.11 | 09:11 am
